Partner Louis-François du Castillon, Counsel Dorothée Vanderhofstadt and Associate Alexandre Denis from our Corporate team advised Santero Therapeutics in their Series A funding.
This funding was led by Newton Biocapital, joined by SFPIM, WE Life Sciences, Sambrinvest, and a group of dedicated business angels led by Pierre Drion.
More than 40 years after the last generation of antibiotics was developed, bacterial resistance is one of the major public health challenges. The World Health Organization (WHO) estimates the phenomenon responsible for five million deaths every year worldwide. SanteroTherapeutics, a spin-off of Université libre de Bruxelles, is dedicated to developing first-in-class antibiotics against multi-drug resistant infections.
This investment will accelerate Santero's revolutionary antibiotic research to combat multi-drug resistant infections
Find more in the press: Santero lève des fonds pour attaquer le "talon d'Achille" des bactéries | L'Echo (lecho.be)
Sign up to our email digest